Discover how prime editing is redefining the future of medicine by offering highly precise, safe, and versatile DNA corrections, bringing hope for more effective treatments for genetic diseases while ...

The biotechnology firm Prime Medicine is approaching what could be its most definitive period. Following its 2025 annual results, the company is shifting its strategic emphasis from initial clinical ...

Like base editing, prime editing offers a safer way to genome editing by relying on a nickase enzyme that “nicks” one DNA strand at a time, rather than cutting both simultaneously. Then, with the ...

Prime Medicine said it has gained FDA clearance for the first human trials of a prime editing therapy as the agency has approved an investigational new drug (IND) application for the company’s first ...

Toward the goal of efficient editing of farm animals for genetic improvements, this study explores an upgraded form of nuclease PE (uPEn). Based on an initial demonstration of its success in editing ...

Scientists have improved a gene-editing technology that is now capable of inserting or substituting entire genes in the genome in human cells efficiently enough to be potentially useful for ...

SAN FRANCISCO—Prime Medicine is on track to file the first IND/CTA application for human trials of a prime editing therapy to the FDA during the first half of this year, with the first clinical data ...

In a study published in Nature Biotechnology, GAO Caixia's group from the Institute of Genetics and Developmental Biology of the Chinese Academy of Sciences has developed a series of new prime editors ...

CAMBRIDGE, Mass., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated, one-time curative genetic ...

For babies born with alternative hemiplegia of childhood (AHC), an extremely rare and severe neurodevelopmental disorder, there may be no obvious symptoms for several months. Then the attacks begin: ...